Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epstein Barr viral shedding dynamics in saliva during acute SARS-CoV-2 infection.

medRxiv : the preprint server for health sciences·2026
Same author

SARS-CoV-2 infectious shedding and rebound among adults with and without oral antiviral use: two case-ascertained prospective household studies.

The Lancet. Microbe·2026
Same author

Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for <i>Galanthus nivalis</i> agglutinin (GNA) affinity resin.

bioRxiv : the preprint server for biology·2025
Same author

Machine Learning Analysis of Post-Acute COVID Symptoms Identifies Distinct Clusters, Severity Groups, and Trajectories.

medRxiv : the preprint server for health sciences·2025
Same author

Long COVID trajectories in the prospectively followed RECOVER-Adult US cohort.

Nature communications·2025
Same author

Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.

JAMA network open·2025
Same journal

Implications of HIV persistence and pathogenesis in microglia.

Current opinion in HIV and AIDS·2026
Same journal

Paediatric HIV cure section in Current Opinion in HIV and AIDS.

Current opinion in HIV and AIDS·2026
Same journal

Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.

Current opinion in HIV and AIDS·2026
Same journal

Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics.

Current opinion in HIV and AIDS·2026
Same journal

Nonhuman primate models of HIV reveal reservoir dynamics and promising interventions.

Current opinion in HIV and AIDS·2026
Same journal

Impact of sex differences in adult and paediatric HIV-1 cure.

Current opinion in HIV and AIDS·2026
See all related articles

Related Experiment Videos

Partial treatment interruptions.

Steven G Deeks1, Jeffrey N Martin

  • 1University of California, San Francisco and San Francisco General Hospital, San Francisco, California 94110, USA. sdeeks@php.ucsf.edu

Current Opinion in HIV and AIDS
|April 18, 2009
PubMed
Summary
This summary is machine-generated.

Strategies for managing drug-resistant HIV focus on maintaining partial viral suppression while reducing drug exposure. Research offers insights into optimizing treatment for patients with limited options, guiding future clinical decisions.

Related Experiment Videos

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Many patients with drug-resistant HIV have limited treatment options for complete viral suppression.
  • Partially suppressive regimens offer clinical benefit but risk resistance mutations and toxicities.
  • New strategies aim to maintain antiviral activity while minimizing drug exposure.

Purpose of the Study:

  • To investigate strategies for maintaining partial activity of HIV therapy while reducing drug exposure.
  • To gain insights into drug mechanisms in the presence of drug-resistant viremia.
  • To inform clinical decision-making for patients with limited therapeutic options.

Main Methods:

  • Review of recent studies on strategies for managing drug-resistant HIV.
  • Analysis of drug activity and resistance mutation profiles.
  • Evaluation of viral fitness and pathogenicity in the context of drug resistance.

Main Results:

  • Nucleoside analogues retain activity against resistant HIV strains.
  • Protease and fusion inhibitors select for resistance mutations that reduce viral fitness.
  • Nonnucleoside reverse transcriptase inhibitors lose efficacy with emerging resistance mutations.

Conclusions:

  • Current strategies are not for routine use but provide proof-of-concept for larger trials.
  • Findings offer valuable insights for 'when to switch,' 'how to switch,' and 'how to wait' in HIV treatment.
  • Further research is needed to validate these approaches in controlled clinical settings.